OOIR: Observatory of International Research

Papers

(The H4-Index of Clinical Kidney Journal is 37. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Prolonged normothermic perfusion: a promising approach to kidney transplantation	229
A puzzling renal Fanconi syndrome	114
Donor-derived membranous nephropathy	100
Circulating miR-129-3p in combination with clinical factors predicts vascular calcification in hemodialysis patients	76
Correction to: Recognition of intraglomerular histological features with deep learning in protocol transplant biopsies and their association with kidney function and prognosis	74
The “Leicester, Leicestershire, and RUtland Chronic Kidney Disease Integrated Care Delivery Project” (LUCID) programme update: the impact on novel kidney therapies	73
Ten tips on management of BK nephropathy in kidney transplant patients	72
Performance of the race-free CKD-EPI creatinine-based eGFR equation in a Danish cohort with measured GFR	65
Meet and greet but avoid the heat: a reflection on the carbon footprint of congresses prompted by ERA2023	64
Differentiating primary and secondary FSGS using non-invasive urine biomarkers	63
Causal relationships between immune cell phenotypes and primary glomerular diseases: genetic evidence from bidirectional Mendelian randomization study	63
Plant-based diets for CKD patients: fascinating, trendy, but feasible? A green nephrology perspective	62
Microvascular perfusion, perfused boundary region and glycocalyx shedding in patients with autosomal dominant polycystic kidney disease: results from the GlycoScore III study	62
Interaction of general obesity and abdominal obesity with frailty in patients with chronic kidney disease: a nationally representative analysis	58
10 tips on performing economic evaluation in kidney disease	57
Novel eGFR equations and cardiovascular outcomes in a multiethnic Asian cohort	56
Erythroferrone is associated with the hepcidin-to-ferritin ratio and cardiovascular mortality in chronic kidney disease	55
Recent advances in pathogenetic concepts and disease modeling of IgA nephropathy	55
Bilateral nephrectomy in autosomal dominant polycystic kidney disease patients before or after renal transplantation: data from a retrospective cohort study	51
Clonal hematopoiesis of indeterminate potential is associated with increased cardiovascular risk in chronic kidney disease	51
Galectin-3 as a prognostic biomarker in haemodialysis patients with preserved or mildly reduced ejection fraction	51
Standardization of serum creatinine is essential for accurate use of unbiased estimated GFR equations: evidence from three cohorts matched on renal function	48
Probability of chronic kidney disease and associated risk factors in Chinese adults: a cross-sectional study of 9 million Chinese adults in the Meinian Onehealth screening survey	47
Informal caregiver burden in dialysis care and how it relates to patients’ health-related quality of life and symptoms	46
Risk factors for acute kidney injury and kidney relapse in patients with lupus podocytopathy	46

Non-invasive assessment of IgA nephropathy severity with [18F]AlF-NOTA-FAPI-04 PET/CT imaging	45
Risk factors for steroid-induced osteonecrosis of the femoral head in children with immune kidney disease	45
Fish oil supplements in patients with chronic kidney disease	43
Biomarkers in clinical epidemiology studies	42
Efficacy and safety of telitacicept, a BLyS/APRIL dual inhibitor, in the treatment of IgA nephropathy: a retrospective case–control study	41
Ten tips on how to manage kidney health in migrants and refugees	40
Complement activation in anti-glomerular basement membrane disease before and after treatment with imlifidase	40
But how green is it actually? Calculating the environmental footprint of kidney care environmental optimizations within haemodialysis	40
Cerebral blood flow following successful living kidney transplantation: the VINTAGE study	39
Obinutuzumab treatment for membranous nephropathy: effectiveness and safety concerns during the COVID-19 pandemic	38
The use of SGLT2 inhibitors and GLP-1 receptor agonists in older patients: a debate on approaches in CKD and non-CKD populations	38
Association between frailty and bone health in early-stage chronic kidney disease: a study from the population-based CARTaGENE cohort	37
Rivaroxaban for the prevention of atherothrombotic events in advanced CKD: are we off TRACK?	37